Loading organizations...
§ Private Profile · Hongo, Tokyo, Japan
Biotech startup developing HSC expansion technology for cell and gene therapies, treating hematologic & genetic disorders.
Celaid Therapeutics is a biotechnology startup based in Bunkyo-ku, Tokyo, Japan, that develops proprietary technology for the selective ex vivo expansion of hematopoietic stem cells. This innovation enables next-generation cell and gene therapies targeting severe hematologic diseases, immunodeficiencies, genetic disorders, and ischemic conditions like leukemia and blood cancers. Founded in October 2020 by Nobuyuki Arakawa and Motoo Watanabe, the venture currently operates with a dedicated team of twelve employees to advance its allogeneic stem cell product pipeline. The enterprise recently raised a 1,055 million JPY Series B first close from prominent backers including The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, and AMED. This latest financing milestone brings the growing company to a cumulative funding total of 2,520 million JPY, or over 17 million USD, across multiple equity rounds and research grants.
Celaid Therapeutics has raised $11.3M across 2 funding rounds.
Celaid Therapeutics has raised $11.3M in total across 2 funding rounds.
Celaid Therapeutics has raised $11.3M in total across 2 funding rounds.
Celaid Therapeutics's investors include Japanese Agency for Medical Research and Development, Joyo Capital Partners, Osaka University Venture Capital, TechnoScience, Atsushi Usami, NEDO, SBI Investment.
Celaid Therapeutics has raised $11.3M across 2 funding rounds. Most recently, it raised $7.0M Series B in October 2025.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 7, 2025 | $7M Series B | — | Japanese Agency For Medical Research And Development, Joyo Capital Partners, Osaka University Venture Capital, Technoscience, Atsushi Usami | Announced |
| May 8, 2024 | $4.3M Grant | — | Joyo Capital Partners, Nedo, Osaka University Venture Capital, SBI Investment, Technoscience, Atsushi Usami | Announced |